Abstract
Beta-blockers, previously considered contraindicated in heart failure are today amongst the most important drugs in heart failure. They improve survival and retard the need for cardiac transplantation. Since most clinical trials demonstrating the benefits of beta-blockers have been done in patients with mild to moderate heart failure, the use of these agents in patients with advanced heart failure remains contraindicated. In this brief review, the author theorizes that due to their immunomodulatory effects, beta-blockers may also play a helpful role in patients presenting cardiogenic shock related to septic shock. However, intensivists should keep in mind that no clinical data are available so far on the role of beta-blockers in septic cardiac shock. Thereby, because the use of beta-blockers in this setting is not established, nor recommended, it should only be applied under controlled trial conditions.
Keywords: Circulatory shock, cardiomyopathy, cardiac depression, anti inflammatory
Current Drug Therapy
Title: Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?
Volume: 1 Issue: 2
Author(s): Karim Bendjelid
Affiliation:
Keywords: Circulatory shock, cardiomyopathy, cardiac depression, anti inflammatory
Abstract: Beta-blockers, previously considered contraindicated in heart failure are today amongst the most important drugs in heart failure. They improve survival and retard the need for cardiac transplantation. Since most clinical trials demonstrating the benefits of beta-blockers have been done in patients with mild to moderate heart failure, the use of these agents in patients with advanced heart failure remains contraindicated. In this brief review, the author theorizes that due to their immunomodulatory effects, beta-blockers may also play a helpful role in patients presenting cardiogenic shock related to septic shock. However, intensivists should keep in mind that no clinical data are available so far on the role of beta-blockers in septic cardiac shock. Thereby, because the use of beta-blockers in this setting is not established, nor recommended, it should only be applied under controlled trial conditions.
Export Options
About this article
Cite this article as:
Bendjelid Karim, Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?, Current Drug Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157488506776930941
DOI https://dx.doi.org/10.2174/157488506776930941 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Gut and Intestinal Bacteria in Chronic Heart Failure
Current Drug Metabolism Generation and Characterization of Developmental Mutations in Xenopus tropicalis
Current Genomics Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation
Cardiovascular & Hematological Agents in Medicinal Chemistry Protein Kinase C Isozymes as Potential Targets for Anticancer Therapy
Current Cancer Drug Targets Glucose Tolerance: Hypothesis Testing on Malaysian Diabetic Community
Current Diabetes Reviews microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design Progress in Detection of Insomnia Sleep Disorder: A Comprehensive Review
Current Drug Targets Targeting of Nuclear Factor-κB and Proteasome by Dithiocarbamate Complexes with Metals
Current Pharmaceutical Design G Protein-Coupled Receptor Signaling Complexity in Neuronal Tissue:Implications for Novel Therapeutics
Current Alzheimer Research Heart Transplantation in Biventricular Congenital Heart Disease: Indications, Techniques, and Outcomes
Current Cardiology Reviews The State of the Problem of Achieving Extremely Low LDL Levels
Current Pharmaceutical Design Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology Extrahepatic Metabolism may Complicate the IVIVC in Rats
Drug Metabolism Letters Selection of Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention
Current Pharmaceutical Design Glycaemic Control: A Balancing Act or A Different Approach?
Current Diabetes Reviews Development of Nitric Oxide Donors for the Treatment of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry The Effects of Exercise on Postpartum Weight Retention in Overweight and Obese Women
Current Women`s Health Reviews Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
Current Cancer Drug Targets Oxidative Stress and Antioxidants in Hypertension–A Current Review
Current Hypertension Reviews Sulfonamides and Sulfonylated Derivatives as Anticancer Agents
Current Cancer Drug Targets